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OBJECTIVE—Obesity is associated with insulin resistance and
type 2 diabetes, although the mechanisms linking these patholo-
gies remain undetermined. Recent studies in rodent models
revealed endoplasmic reticulum (ER) stress in adipose and liver
tissues and demonstrated that ER stress could cause insulin
resistance. Therefore, we tested whether these stress pathways
were also present in obese human subjects and/or regulated by
weight loss.
RESEARCH DESIGN AND METHODS—Eleven obese men
and women (BMI 51.3  3.0 kg/m
2) were studied before and 1 year
after gastric bypass (GBP) surgery. We examined systemic insulin
sensitivity using hyperinsulinemic-euglycemic clamp studies before
and after surgery and collected subcutaneous adipose and liver
tissues to examine ER stress markers.
RESULTS—Subjects lost 39  9% body wt at 1 year after GBP
surgery (P  0.001), which was associated with a marked improve-
ment in hepatic, skeletal muscle, and adipose tissue insulin sensi-
tivity. Markers of ER stress in adipose tissue signiﬁcantly decreased
with weight loss. Speciﬁcally, glucose-regulated protein 78 (Grp78)
and spliced X-box binding protein-1 (sXBP-1) mRNA levels were
reduced, as were phosphorylated elongation initiation factor 2
(eIF2) and stress kinase c-Jun NH2-terminal kinase 1 (JNK1) (all P
values 0.05). Liver sections from a subset of subjects showed
intense staining for Grp78 and phosphorylated eIF2 before sur-
gery, which was reduced in post-GBP sections.
CONCLUSIONS—This study presents important evidence that
ER stress pathways are present in selected tissues of obese
humans and that these signals are regulated by marked weight
loss and metabolic improvement. Hence, this suggests the pos-
sibility of a relationship between obesity-related ER stress and
metabolic dysfunction in obese humans. Diabetes 58:693–700,
2009
I
ncreased adiposity is associated with a group of
chronic metabolic disorders, including insulin resis-
tance, type 2 diabetes, and nonalcoholic fatty liver
disease (1). The prevalence of this cluster of abnor-
malities has increased signiﬁcantly in the past few decades
following the marked rise of obesity worldwide (2,3). The
mechanisms responsible for the emergence of these dis-
orders have been an intense area of investigation. In the
past decade, it was recognized and established that
chronic inﬂammatory and stress responses are a central
feature of obesity, insulin resistance, and type 2 diabetes
and contribute to the metabolic imbalance (4). However,
the pathways and mechanisms giving rise to the chronic
inﬂammatory responses remain to be elucidated.
Recently, we have identiﬁed endoplasmic reticulum
(ER) dysfunction as a signiﬁcant contributor to the devel-
opment of experimental insulin resistance in obese tissues
(5). The ER is a critical intracellular organelle that coor-
dinates the synthesis, folding, and trafﬁcking of proteins.
All transmembrane and secreted proteins pass through the
ER en route to cellular destinations; proteins that fail to
fold into proper structures are removed from the ER
through degradation. Under stress conditions, unfolded
proteins accumulate in the ER and initiate an adaptive
response known as the unfolded protein response (UPR).
The UPR is initiated by three ER transmembrane sensors
[namely PKR-like ER-regulated kinase (PERK), inositol-
requiring enzyme-1 (IRE-1), and activating transcription
factor-6 (ATF-6)], which activate an adaptive response
that results in cessation of protein translation and tran-
scriptional increase in protein-folding chaperones and
ER-associated degradation genes (6). If the stress is too
severe, the UPR may also induce cellular apoptosis
through several different mechanisms involving the vari-
ous branches of the UPR. In mouse models of obesity, ER
stress is present in liver and adipose tissues, as evidenced
by increased activity of both the IRE-1 and PERK branches
(7). The UPR is also able to induce activation of the c-Jun
NH2-terminal kinase (JNK) pathway and thereby inhibit
insulin signaling through the subsequent phosphorylation
and/or degradation of IRS1 (7–9). Data obtained from
mouse models demonstrate that genetically compromised
ER folding capacity induces ER stress, activates JNK, and
leads to whole-body insulin resistance in the mouse (7). In
contrast, enhancing ER capacity in obese mice through the
use of chemical or molecular chaperones relieves ER
stress in adipose tissue and liver, reduces intrahepatic fat
accumulation, and restores glucose homeostasis (10).
Although ER stress is associated with obesity and
metabolic dysfunction in rodent models, the importance of
ER stress in the pathogenesis of obesity-related metabolic
disease and the potential regulation of ER function by
weight loss in human subjects is not known. Therefore, the
purpose of the present study was to evaluate the effect of
marked weight loss induced by gastric bypass (GBP)
surgery on insulin sensitivity and ER stress in key meta-
bolic tissues in obese human subjects. A euglycemic-
hyperinsulinemic clamp procedure, in conjunction with
stable isotopically labeled tracer infusions, was used to
assess insulin action in liver, skeletal muscle, and adipose
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DIABETES, VOL. 58, MARCH 2009 693tissue; and UPR markers from among the three response
branches were evaluated in liver and adipose tissue sam-
ples obtained before and 1 year after GBP surgery.
RESEARCH DESIGN AND METHODS
Subjects and GBP surgery. Eleven obese subjects (mean BMI 51.3  3.0
kg/m
2; two men and nine women) who were scheduled to undergo GBP
surgery participated in this study. All subjects completed a comprehensive
medical evaluation, which included a detailed history and physical examina-
tion, routine blood tests, and a 12-lead electrocardiogram. No subjects had
diabetes, had other metabolic diseases, or were taking medications that affect
insulin action or glucose and fatty acid metabolism. All subjects gave their
written informed consent before participating in this study, which was
approved by the Human Research Protection Ofﬁce and the Center for Applied
Research Sciences Advisory Committee of Washington University School of
Medicine.
All GBP procedures were performed by the same surgeon (J.C.E.) using
standard surgical techniques. All patients had an open GBP procedure, which
involved constructing a small (20 ml) proximal gastric pouch by stapling
across the stomach. A 150-cm Roux-Y limb was constructed by transecting the
jejunum 30 cm distal to the ligament of Treitz and creating a jejunojejunos-
tomy 150 cm distal to the transection.
Metabolic studies and sample analyses. Insulin sensitivity was examined
by using the hyperinsulinemic-euglycemic clamp procedure in 10 of the 11
subjects before and 1 year after GBP surgery. Subjects were admitted to the
Intensive Research Unit at Washington University School of Medicine on the
evening before the clamp procedure. The following morning, after subjects
fasted overnight, a one-stage hyperinsulinemic-euglycemic clamp procedure
was performed; [6,6-
2H2]glucose and [2,2-
2H2]palmitate were infused for 6 h
(0- to 3-h basal period followed by 3- to 6-h insulin infusion at a rate of 15 mU 
m
2 body surface area [BSA]  min
1, initiated with a priming dose of 60 mU 
m
2 BSA  min
1 for 5 min and then 30 mU  m
2 BSA  min
1 for 5 min.
Euglycemia was maintained at a blood glucose concentration of 5.6 mmol/l
(100 mg/dl) throughout the clamp procedure by infusing 20% dextrose
enriched to 2.5% with [6,6-
2H2]glucose. Blood samples were obtained before
beginning the tracer infusion to determine background plasma glucose and
palmitate tracer-to-tracee ratios and every 10 min during the ﬁnal 30 min of the
basal period and of the clamp procedure to determine glucose and insulin
concentrations and substrate kinetics. Plasma insulin was determined by a
radioimmunoassay and plasma glucose and palmitate tracer-to-tracee ratios
were determined by using gas chromatography–mass spectroscopy (MSD
5973 system with capillary column; Hewlett-Packard, Palo Alto, CA), as
previously described (11,12). Glucose and palmitate kinetics were determined
by using Steele’s equation for steady-state conditions (13,14), and hepatic
insulin sensitivity was determined by the reciprocal of the hepatic insulin
resistance index [10,000/(basal glucose rate of appearance (Ra)i nmol  kg
1
 min
1  basal insulin concentration in mU/l)], as previously described
(15,16).
Subcutaneous abdominal adipose tissue samples were collected during
basal postabsorptive conditions in all subjects by using a 14-gauge needle;
samples were immediately frozen in liquid nitrogen. Liver tissue samples were
obtained by needle biopsy during GBP surgery and by percutaneous needle
biopsy 1 year after GBP surgery in four subjects and placed in formalin for
further analyses.
mRNA isolation and quantitative PCR. Frozen adipose tissue samples
were homogenized in TRIzol Reagent (Invitrogen) for total RNA isolation
according to the manufacturer’s protocol. cDNA synthesis was performed
using 1 g sample RNA reverse transcribed with the high-capacity cDNA
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FIG. 1. Alterations in systemic insulin sensitivity in GBP subjects.
Hepatic insulin sensitivity index, calculated as the reciprocal of the
product of basal glucose production and insulin concentration (A);
insulin-stimulated glucose disposal, an index of skeletal muscle insulin
sensitivity assessed as the relative increase in glucose uptake during
insulin infusion (B); and insulin-mediated suppression of palmitate Ra
into plasma, an index of adipose tissue insulin sensitivity assessed as
the relative decrease in palmitate Ra during insulin infusion (C), in
obese subjects before (f) and 1 year after () GBP surgery. *Value
signiﬁcantly different from the before GBP value; *P < 0.01, **P <
0.001.
TABLE 1
Metabolic characteristics of subjects before and 1 year after
gastric bypass surgery
Before
surgery
After
surgery
n (men/women) 10 (2/8) 10 (2/8)
Age 40.3  2.3 41.3  2.3
Weight (kg) 143.5  9.44 87.6  5.9*
BMI (kg/m
2) 51.3  3.0 31.4  2.3*
Glucose (mg/dl) 98.5  4.8 84.2  2.2†
Insulin (mU/l) 18.7  3.1 4.9  0.8*
HOMA-IR 5.3  0.9 1.6  0.5†
Intrahepatic fat content (%)‡ 19.5  5.2 1.9  2.1*
Systolic blood pressure (mm/Hg) 132  7 108  5*
Diastolic blood pressure (mm/Hg) 74  36 3  4†
Total cholesterol (mg/dl) 160  13 161  9
LDL cholesterol (mg/dl) 85  10 79  6
HDL cholesterol (mg/dl) 48  46 8  5§
Triglyceride (mg/dl) 135  19 72  9†
Data are means  SE. Value signiﬁcantly different from correspond-
ing Before Surgery value; *P  0.001; †P  0.05; §P  0.01. ‡Data
from four subjects. HOMA-IR, homeostasis model assessment oﬁn-
sulin resistance.
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694 DIABETES, VOL. 58, MARCH 2009archive system (Applied Biosystems, Foster City, CA). Real-time, quantitative
PCR was performed using SybrGreen reagent in the ABI 7300 real-time PCR
system (Applied Biosystems) to determine the mRNA levels of the following
genes in adipose tissue samples obtained before and after GBP surgery: 18S,
C/EBP homologous protein (CHOP), spliced X-box binding protein-1 (XBP-1),
glucose-regulated protein 78 (Grp78), and interleukin-6 (IL-6). Primer se-
quences used to detect these human genes are as follows: 18S forward,
GTAACCCGTTGAACCCCATT; 18S reverse, CCATCCAATCGGTAGTAGCG;
Grp78 forward, CATCACGCCGTCCTATGTCG; Grp78 reverse, CGTCAAA-
GACCGTGTTCTCG; sXBP forward, GGTCTGCTGAGTCCGCAGCAGG; sXBP
reverse, GGGCTTGGTATATATGTGG; CHOP forward, GGAGAACCAG-
GAAACGGAAAC; CHOP reverse, TCTCCTTCATGCGCTGCTTT; IL-6 forward,
AAATTCGGTACATCCTCGACGG; and IL-6 reverse, GGAAGGTTCAGGTT-
GTTTTCTGC.
Protein isolation, antibodies, and Western blotting. Frozen adipose
tissue samples were homogenized in lysis buffer containing 25 mmol/l Tris-HCl
(pH 7.4), 10 mmol/l Na3VO4, 100 mmol/l NaF, 50 mmol/l Na4P2O7, 10 mmol/l
EGTA, 10 mmol/l EDTA, and 1% Nonidet P-40 with protease inhibitors
(Sigma). After homogenization, the tissue lysate was centrifuged at 4,000 rpm
for 15 min at 4°C followed by 14,000 rpm for 20 min at 4°C. Eighty micrograms
total tissue protein was used for direct immunoblotting. Rabbit polyclonal
anti–phosphorylated eukaryotic initiation factor 2 (eIF2) antibody (Invitro-
gen) was used at 1:1,000 dilution; mouse monoclonal anti–phosphorylated
JNK (Cell Signaling) was used at 1:1,000 dilution; rabbit polyclonal anti-
calnexin (Stressgen) was used at 1:1,000 dilution; -tubulin (Santa Cruz) was
used at 1:1,000 dilution. Horseradish peroxidase–linked anti-mouse or anti-
rabbit secondary antibody (GE Healthcare) was used at 1:4,000 dilution.
Immunohistochemical examination of liver sections. Liver biopsy speci-
mens were evaluated for steatosis and inﬂammation by hematoxylin-eosin
(H-E) staining and for markers of ER stress by using immunohistochemistry.
Human liver sections were subjected to routine deparaﬁnization/hydration
process and blocked with goat serum albumin for1ha troom temperature.
Primary antibody incubation at 1:50 concentration was performed overnight
at 4°C. After primary antibody incubation, sections were washed with PBS and
incubated with secondary antibody at 1:200 dilution for 60 min. At the end of
the secondary antibody incubation, sections were washed with PBS followed
by application of mounting solution containing DAPI (Vector Lab). Secondary
antibodies used in the current study were ﬂuorescein isothiocyanate– or
Texas-red–conjugated anti-rabbit IgG (Santa Cruz). Negative controls in-
cluded omission of the primary antibody. Cells were examined with a
ﬂuorescence microscope (Axio Observer; Carl Zeiss). Quantiﬁcation of immu-
nohistochemical staining was performed using Axiovision Software (Carl
Zeiss) from images of liver tissue captured at random and is represented as
relative ﬂuorescence intensity.
Selection of UPR markers. We chose UPR markers from among the three
branches that respond to ER stress. The transmembrane kinase PERK
phosphorylates eIF2, leading to inhibition of general protein translation. As
a result of alternative translation, the proapoptotic transcription factor CHOP
is induced. IRE-1 activates the stress kinase JNK1 and also possesses
endoribonuclease activity, which splices an intron from the mRNA of XBP-1,
creating an activated transcription factor. Spliced XBP-1, along with active
ATF-6, translocates to the nucleus and induces expression of protein chaper-
one genes. One well-known target of both of these transcription factors is the
chaperone Grp78.
Statistical analyses. Insulin sensitivity and patient information datasets
were normally distributed according to the Kolmogorov-Smirnov test, so that
comparisons between subjects before and after weight loss were performed
using parametric procedures. The statistical signiﬁcance of the effect of
insulin infusion on substrate metabolism before and after weight loss was
analyzed by using the Student’s t test for paired samples. Results are
presented as means  SE. All reported P values are two sided, and a P value
of 0.05 was considered to be statistically signiﬁcant.
RESULTS
Study subject characteristics and insulin sensitivity.
On average, subjects lost 40% of their initial body weight
at 1 year after GBP surgery (Table 1). Weight loss caused
a marked decrease in plasma glucose and insulin concen-
trations and in intrahepatic fat content (Table 1). The
hepatic insulin sensitivity index value was 160% greater 1
year after than before GBP surgery (P  0.01) (Fig. 1A).
Insulin infusion during the clamp procedure increased
plasma insulin concentration from 18.7  3.1 to 43.6  4.2
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FIG. 2. Regulation of spliced XBP-1 mRNA in GBP subjects. Quantitative RT-PCR was performed on RNA isolated from adipose tissue of patients
before and after GBP surgery, n  11. A: Percent change in sXBP-1 mRNA from pre-GBP levels in each individual patient. B: Pre- and post-GBP
surgery levels of sXBP-1 mRNA normalized to 18S ribosomal RNA. C: Average mRNA levels for sXBP-1 in pre and post-GBP surgery groups. Data
indicate means  SE. *P < 0.05.
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DIABETES, VOL. 58, MARCH 2009 695mU/l before and from 4.9  0.8 to 27.0  1.5 mU/l 1 year
after GBP surgery. Plasma glucose concentrations during
insulin infusion were 97.7  1.7 and 99.6  1.9 mg/dl
during the clamp procedure performed before and after
weight loss, respectively. Insulin infusion caused an in-
crease in glucose Rd from 1,081  69 to 1,418  108
mol/min before GBP surgery and from 813  57 to
1,666  171 mol/min 1 year after GBP surgery. The
increase in glucose Rd during insulin infusion was 200%
greater after than before weight loss (P  0.01) (Fig. 1B).
Insulin infusion caused a decrease in palmitate Ra from
161  13 mol/min to 61  14 mol/min before GBP
surgery and from 105  9t o2 1 4 mol/min 1 year after
GBP surgery. Insulin-mediated suppression of palmitate Ra
was 23% greater 1 year after than before weight loss (P 
0.01) (Fig. 1C). Taken together, these data demonstrate
marked metabolic improvement in subjects after weight
reduction by GBP surgery.
Adipose tissue expression and regulation of UPR-
related genes. The expression of UPR induced genes in
subcutaneous abdominal adipose tissue was evaluated in
all 11 subjects before and 1 year after GBP surgery. We
ﬁrst examined the splicing of the XBP-1 mRNA, a critical
transcription factor and indicator of ER stress and adap-
tive responses. After GBP, there was an average 47.5%
reduction (P 	 0.04) in spliced XBP-1 mRNA compared
with levels in pre-GBP tissues (Fig. 2C). When examined
individually, sXBP-1 levels were decreased in 9 of the 11
subjects (Fig. 2A and B). Next, we examined the expres-
sion of GRP78 mRNA because this chaperone can be
targeted by sXBP-1 and also by ATF-6, the second tran-
scription factor regulating the UPR. As seen in Fig. 3, the
levels of Grp78 mRNA were signiﬁcantly decreased in
post-GBP tissues, with an average 40.1% reduction in
mRNA post-GBP (P 	 0.01). When examined individually,
decreased Grp78 gene expression was evident in 7 of 11
subjects (Fig. 3A and B), suggesting that its regulation may
be greater in variability than sXBP-1. In contrast, adipose
tissue CHOP expression was not signiﬁcantly different
between the samples collected before or after surgery
(Fig. 4). Interestingly, in rodent models of obesity, we also
did not detect a signiﬁcant regulation of CHOP mRNA
expression between lean and obese WAT (M.F.G., G.S.H.,
unpublished data). Adipose tissue IL-6 expression was
determined to compare the UPR changes to a well-estab-
lished inﬂammatory alteration. Earlier studies have shown
that IL-6 expression is signiﬁcantly and consistently
downregulated in adipose tissue after weight loss (17–21).
Consistent with these observations, IL-6 mRNA levels
were also signiﬁcantly reduced in 8 of 11 subjects after
GBP (Fig. 4).
Regulation of biochemical markers of ER stress in
adipose and liver. The presence of tissue ER stress in
obesity in rodents is best evaluated by the phosphorylation
of PERK, IRE-1, or eIF2 and stimulation of JNK activity,
because these are more proximal measures of UPR activ-
ity (7). Because there are no antibodies that can detect the
phosphorylated form of PERK or IRE-1 in humans yet, we
ﬁrst measured the phosphorylated form of eIF2 in adi-
pose tissue before and after GBP. Figure 5 reveals the
presence of robust eIF2 phosphorylation in adipose
tissue in all obese subjects. Remarkably, there was a
signiﬁcant reduction in the phosphorylation of adipose
tissue eIF2 after GBP surgery, which was observed in all
of the subjects studied (P  0.0001). We also examined the
activity of JNK, which can be activated through the IRE-1
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FIG. 3. Regulation of Grp78 mRNA in GBP subjects. Quantitative RT-PCR was performed on RNA isolated from adipose tissue of patients before
and after GBP, n  11. A: Percent change in Grp78 mRNA from pre-GBP levels in each individual patient. B: Pre- and post-GBP surgery levels of
Grp78 mRNA normalized to 18S ribosomal RNA. C: Average mRNA levels for Grp78 in pre- and post-GBP groups. Data indicate mean  SE. *P <
0.02.
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determined by phosphorylation of the JNK1 isoform, was
detectable in the obese subjects before GBP surgery. As
shown in Fig. 5C, JNK phosphorylation also signiﬁcantly
decreased in adipose tissue after GBP surgery. Taken
together, these observations indicate alleviation of ER
stress in adipose tissue after substantial weight loss.
In a subgroup of four subjects, liver biopsy samples
were obtained before and 1 year after GBP surgery. H-E
staining of the liver sections demonstrated a 90% decrease
in intrahepatic triglyceride content after GBP surgery
(Table 1; Fig. 6A). In this limited number of samples, we
were also able to examine the effects of weight loss on
eIF2 phosphorylation and GRP78 protein levels by im-
munohistochemistry. Immunostaining with an anti–phos-
pho-eIF2 antibody revealed strong immunoreactivity in
liver sections obtained before GBP (Fig. 6). Similarly,
immunostaining with an antibody against the ER chaper-
one GRP78 revealed strong staining in the obese subjects
before GBP. Particularly, areas surrounding the lipid drop-
lets revealed intense staining. In the samples obtained
after weight loss, immunoreactivity against both phospho-
eIF2 and GRP78 was reduced either in general intensity
or number of areas. In some cases, the signal was reduced
markedly (Fig. 6; supplemental Fig. 1, available in an
online appendix at http://dx.doi.org/10.2337/db08-1220),
and in others, it was reduced partially and with residual
and scattered signal. Although variable among subjects,
these results indicate that similar to adipose tissue, obe-
sity in humans may also be associated with ER stress in
liver tissue, which is ameliorated upon weight loss.
DISCUSSION
Recent data from studies conducted in obese rodent
models have demonstrated that ER stress and the activa-
tion of related stress signaling pathways may be an impor-
tant mechanism underlying insulin resistance and type 2
diabetes (5). The results of the present study demonstrate
that in obese humans, ER stress is present in adipose and
liver tissues and is highly regulated by weight loss induced
by GBP surgery.
GBP surgery is the most commonly performed bariatric
surgical procedure in the U.S. and worldwide and is an
effective approach for achieving weight loss in obese
patients (1). Weight loss induced by GBP surgery improves
or completely resolves most obesity-related medical com-
plications and increases survival (22,23). We chose to
investigate ER stress in patients who had GBP surgery so
that comparisons could be made within the same individ-
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FIG. 4. CHOP (left panel) and IL-6 (right panel) mRNA levels in GBP subjects. Quantitative RT-PCR was performed on RNA isolated from adipose
tissue of patients before and after GBP, n  11. A: Percent change in CHOP and IL-6 mRNA from pre-GBP levels in each individual patient. B: Pre-
and post-GBP levels of CHOP and IL-6 mRNA normalized to 18S ribosomal RNA. C: Average mRNA levels for CHOP and IL-6 in pre- and post-GBP
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treme weight loss. This approach has several important
strengths. First, each individual served as his/her own
control, which removes confounding variables that may
not necessarily be accounted for if the control group
comprised a different cohort. Second, by measuring
change over time within an individual, we are able to
capture the state of the ER in ﬂux. This is important given
the highly dynamic nature of the ER, which adjusts its
adaptive capacity to the condition of the cells and to
environmental and intrinsic stress signals, such as alter-
ations in metabolism and body weight. Given the ﬂuctuat-
ing environment of the cell and the adaptive responses of
the ER, a solitary UPR molecule may not a reliable
indicator of ER functional capacity. Therefore, we mea-
sured multiple markers of ER stress to assess the different
UPR pathways, ranging from proximal biochemical activ-
ities of the sensors, to their substrates, to the downstream
transcriptional outcomes of target gene expression.
Our data clearly demonstrate a signiﬁcant regulation of
ER stress upon weight loss, as evidenced by the suppres-
sion of biochemical indicators of ER stress such as eIF2
and JNK phosphorylation, and downregulation of UPR
transcriptional arms via spliced XBP-1 and Grp78. Given a
relatively small patient number, we observed remarkably
consistent effects on ER stress in post-GBP tissues. It is
interesting that despite marked suppression of eIF2
phosphorylation in adipose tissue upon weight loss, there
was no change in the levels of CHOP mRNA expression,
which is generally considered to be downstream of eIF2
phosphorylation. It is possible that CHOP is regulated
through other signals and does not respond to changes in
body weight. In fact, in our recent work in rodent models
comparing adipose tissue samples obtained from genetic
and dietary models of obesity with lean controls subjects,
we did not observe any change in the expression levels of
CHOP mRNA (unpublished results). Nonetheless, our ﬁnd-
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FIG. 5. Adipose tissue p-eIF2 and p-JNK levels after GBP surgery. Protein expression levels of p-eIF2 and p-JNK in adipose tissue from
patients before and after GBP were detected by Western blot assay, followed by densitometric analysis. A: Pre- and post-GBP levels of p-eIF2
and p-JNK normalized to calnexin. B: Average levels of p-eIF2 and p-JNK in pre- and post-GBP groups. C: Immunoblot analyses of p-eIF2 and
p-JNK expression levels in patients 67, 68, and 71 before and after GBP. Data indicate means  SE. *P < 0.05. (Please see http://dx.doi.org/10.
2337/db08-1220 for a high-quality digital representation of this ﬁgure.)
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regulated by obesity and weight loss in humans.
The mechanism responsible for weight loss–induced
reduction in ER stress in our subjects is not known.
Potential factors may include the decrease in adipose and
liver triglyceride content or the decrease in systemic
plasma insulin and glucose concentrations. Although it is
unclear how these factors inﬂuence ER stress, data from
in vitro studies suggest that inﬂammation, reactive oxygen
species, saturated fatty acids, or hypoxia could also be
involved. These signals have all been shown to compro-
mise ER folding capacity and/or induce ER stress in vitro
and have also been described in obese, insulin-resistant
tissues (5). Nonetheless, the in vivo physiological mecha-
nisms/causes remain unknown.
Two recent studies utilizing lean and obese cohorts have
demonstrated regulation of ER stress markers. Boden
et al. (24) reported an increase in ER stress proteins and
gene expression in subcutaneous adipose tissue in obese
individuals compared with lean. A second study measured
ER stress markers within a range of BMIs and found a
signiﬁcant positive correlation with increasing BMI (25).
These data support the hypothesis that obesity leads to
increased ER stress in adipose tissue and complements
our ﬁndings of the effect of weight loss on tissue stress.
Interestingly, recent studies have also provided evi-
dence that ER stress pathways are activated in pancreatic
islets in type 2 diabetes and in atherosclerotic vascular
lesions (26,27). Although this is a relatively young ﬁeld,
these observations have raised the possibility that ER
dysfunction and the resulting stress responses may be
important components of chronic metabolic diseases in a
broader sense. The extent to which these pathways will be
relevant to human metabolic diseases, particularly obesity
and type 2 diabetes, remains a critical but unanswered
question.
In summary, the results from the present study demon-
strate that human obesity is associated with insulin resis-
tance and ER stress in both adipose tissue and the liver.
Weight loss is associated with decreased ER stress and
improved insulin sensitivity, suggesting the possibility that
the ER is involved in regulating insulin action in obese
humans. These ﬁndings, while correlative, are consistent
with data from studies conducted in rodent models, which
have found that obesity is associated with ER stress and
that ameliorating ER stress improves insulin action. There-
fore, the ER could be an important new target for treating
the metabolic complications of obesity.
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